Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 4, 2022

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) will report its second quarter 2022 financial results on August 4, 2022, at 8:00 AM ET. A conference call and webcast will follow to discuss the financial outcome and provide updates on corporate developments. Investors can access the live webcast through the company’s website, and a replay will be available later. Deciphera is focused on innovative cancer medicines, notably the switch control inhibitor QINLOCK®, approved in several regions including the US and Europe.

Positive

• QINLOCK® is approved in multiple markets, enhancing revenue potential.
• The upcoming earnings call provides an opportunity for transparency and updates.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ET on Thursday, August 4, 2022, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed via this link: https://register.vevent.com/register/BI14cfe386c5004efcba5c94f8783e2435.

A live webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay will be available on the Company’s website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005200/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When will Deciphera Pharmaceuticals report its Q2 2022 financial results?

Deciphera Pharmaceuticals will report its Q2 2022 financial results on August 4, 2022.

What time is Deciphera Pharmaceuticals' earnings call?

The earnings call for Deciphera Pharmaceuticals is scheduled for 8:00 AM ET on August 4, 2022.

How can I access the Deciphera Pharmaceuticals earnings call?

You can access the Deciphera Pharmaceuticals earnings call via their website or through the provided registration link.

What is QINLOCK® by Deciphera Pharmaceuticals?

QINLOCK® is Deciphera's switch control inhibitor for the treatment of fourth-line GIST, approved in several countries.

Where is QINLOCK® approved?

QINLOCK® is approved in the US, EU, Australia, Canada, China, Hong Kong, Switzerland, Taiwan, and the UK.